OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin

?Multicenter study of a single arm to evaluate the safety of eribulin in 3rd line chemotherapy for patients with HER2-negative metastatic or locally advanced previously treated with anthracyclines and taxanes: Onsite Study" - ONCOSUR-2012-02

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-001416-30-ES

Enrollment

Registered

2013-09-05

Start date

2013-10-17

Completion date

Unknown

Last updated

2016-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: HALAVEN 0,44 mg/ml solución inyectable Product Name: halaven Pharmaceutical Form: Solution for injection INN or Proposed INN: ERIBULIN CAS Number: 441045-17-6 Other descriptive name: ERIBU

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 60

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
Main Objective: -;Secondary Objective: -;Primary end point(s): -;Timepoint(s) of evaluation of this end point: -	—

Secondary

Measure	Time frame
Secondary end point(s): -;Timepoint(s) of evaluation of this end point: -	—

Countries

Spain

Contacts

Public ContactArancha Maciá

EXPERIOR

macia.arancha@experior.es0034902105 255129

Outcome results